Skip to main content
WST logo

WST · West Pharmaceutical Services Inc · Financials

Track WST — free
Market Cap
$29.01B
Shares
69.66M
Volume · Nov 16 84.42K Avg daily vol (3M) 601.93K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$3.07B +6.3%
FY2025 Revenue FY2008–FY2025
Net Income
$493.7M +0.2%
FY2025 Net Income FY2008–FY2025
Gross Margin
35.91% +1.4pp
FY2025 Gross Margin FY2008–FY2025
Operating Margin
19.03% -0.7pp
FY2025 Operating Margin FY2008–FY2025
Diluted EPS
$6.79 +1.5%
FY2025 Diluted EPS FY2008–FY2025
Operating Cash Flow
$754.8M +15.5%
FY2025 Operating Cash Flow FY2008–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2026 (G) TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010 FY2009 FY2008
$3.41B – $3.42B $3.4B $3.07BG $2.89B $2.95BG $2.89BG $2.83BG $2.15BG $1.84B $1.72B $1.6B $1.51B $1.4B $1.42B $1.37B $1.27B $1.19B $1.1B $1.06B $1.05B
— $2.12B $1.97B $1.89B $1.82B $1.75B $1.66B $1.38B $1.23B $1.17B $1.09B $1.01B $944M $973.6M $933.7M $878.7M $853M $786.6M $752.1M $748.5M
— $1.28B $1.1B $998.5M $1.13B $1.14B $1.18B $767.8M $605.7M $545.4M $512.9M $501.4M $455.8M $447.8M $434.7M $387.7M $339.3M $318.1M $303.6M $302.6M
— — 35.91% 34.51% 38.28% 39.36% 41.52% 35.76% 32.92% 31.76% 32.07% 33.23% 32.56% 31.5% 31.77% 30.61% 28.46% 28.8% 28.76% 28.79%
— $75.6M $74.3M $69.1M $68.4M $58.5M $52.8M $46.9M $38.9M $40.3M $39.1M $36.8M $34.1M $37.3M $37.9M $33.2M $29.1M $23.9M $19.9M $18.7M
— $437M $393.6M $338.5M $353.4M $316.9M $362.8M $302M $272.7M $262.9M $246M $239.6M $233M $228.7M $234.9M $218.1M $191.1M $187.7M $177.7M $159.3M
— — $2.8M $3.6M $3.6M $3.7M $5.4M $4.4M $3.4M $2.7M $2.4M $2.6M $3.5M $4.9M $3.9M $3.9M $4.3M $4.1M — —
— $184.3M $171.4M $155.4M $137.3M $120.6M $122.3M $109.1M $103.4M $104.4M $96.7M $90.7M $89.9M $90M $85.2M $76.9M $75.7M $73.2M $68.1M —
— — — — — — — — — — — $26.4M — — — $2.1M $5.3M — — —
— $780.2M $584.9M $569.9M $676M $734M $752.3M $406.9M $296.6M $240.3M $225.8M $195.2M $128.6M $182M $162.4M $135.1M $109.6M $90.7M $97.5M $124.1M
— — 19.03% 19.7% 22.92% 25.43% 26.57% 18.95% 16.12% 13.99% 14.12% 12.93% 9.19% 12.8% 11.87% 10.67% 9.19% 8.21% 9.24% 11.81%
— $964.5M $756.3M $725.3M $813.3M $854.6M $874.6M $516M $400M $344.7M $322.5M $285.9M $218.5M $272M $247.6M $212M $185.3M $163.9M $165.6M —
— $8.1M $500K $3M $9M $7.9M $8.2M $8.2M $8.5M $8.4M $7.8M $8.1M $14.1M $16.5M $17M $16.7M $18.2M $16.8M $15.2M $16M
— -$1M -$1M -$1M $22M -$54.1M -$3.4M -$5.6M -$4.8M $400K $3.1M $1.6M — — — — $4.2M -$100K -$200K —
— $17.7M $14.4M $14.7M $17.7M $20.7M $20.1M $17.4M $8.9M $7.6M $9.2M $8.2M $5.8M $5.3M $5.4M $4.8M $6.3M $4.4M $3M $800K
— — — — -$4.3M -$3.5M -$4.3M -$2.5M $0 — — — — — — — — — — —
— $789.4M $600.9M $585.5M $698M $679.9M $748.9M $401.3M $291.8M $240.7M $222.4M $189.8M $116.1M $169M $147.1M $108.6M $92.7M $74.5M $83.1M $109.5M
— $168.2M $121.6M $107.5M $122.3M $114.7M $107.2M $72.5M $59M $41.4M $80.9M $54.4M $26.3M $47.2M $40.2M $32.7M $23.5M $13.6M $13.5M $23.7M
— $638.9M $493.7M $492.7M $593.4M $585.9M $661.8M $346.2M $241.7M $206.9M $150.7M $143.6M $95.6M $127.1M $112.3M $80.7M $75.5M $65.3M $72.6M $86M
— — 16.06% 17.03% 20.12% 20.3% 23.37% 16.13% 13.14% 12.05% 9.42% 9.52% 6.83% 8.94% 8.21% 6.37% 6.33% 5.91% 6.88% 8.18%
— — — — — — — — — — — — — — — — — $0 $0 $600K
— $604.2M $646.3M $378.4M $632.6M $562.5M $612.8M $385.2M $246.3M $170M $220.2M $119.4M $52.2M $40.3M $155.8M $76.3M $35.3M $53.7M $97.8M $7.5M
USD/shares — $8.97 $6.83 $6.75 $7.98 $7.87 $8.89 $4.68 $3.27 $2.80 $2.04 $1.96 $1.33 $1.79 $1.61 $1.19 $1.12 $1.96 $2.21 $2.65
USD/shares $9.31 – $9.41 $8.91 $6.79G $6.69G $7.88G $7.73G $8.67G $4.57G $3.21 $2.74 $1.99 $1.91 $1.30 $1.75 $1.57 $1.15 $1.08 $1.89 $2.12 $2.50
shares — — 72.3M 73M 74.3M 74.4M 74.4M 73.9M 74M 73.9M 73.9M 73.3M 72M 70.9M 69.6M 68.1M 67.3M 33.3M 32.8M 32.4M
shares — — 72.7M 73.7M 75.3M 75.8M 76.3M 75.8M 75.4M 75.4M 75.8M 75M 73.8M 72.8M 71.4M 71.8M 74M 36.7M 36.3M 36.1M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2025: $1.89B in buybacks, $689.4M in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →
Latest reported total
USD 202,900,000
As of Jun 30, 2026
Tracked instruments
0
Loans, facilities and note series
Annual baseline
—
Latest approved annual total
Reported total debt history
As of Reported label Amount Source
2026-06-30 total debt balance USD 202,900,000 10-Q filed 2026-07-23
Debt and credit facilities – The total debt balance of $202.9 million at June 30, 2026 is consistent with the total debt balance of $202.8 million at December 31, 2025.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Finance lease liabilities 2026-09-30 USD 8,900,000 10-Q filed 2026-10-29
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current finance lease liabilities
USD 1,400,000
Noncurrent finance lease liabilities
USD 7,500,000
Long-term debt, including current maturities 2026-09-30 USD 202,900,000 10-Q filed 2026-10-29
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current portion of long-term debt
USD 0
Noncurrent debt carrying amount
USD 202,900,000
Operating lease liabilities 2026-09-30 USD 102,100,000 10-Q filed 2026-10-29
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current operating lease liabilities
USD 19,500,000
Noncurrent operating lease liabilities
USD 82,600,000
4 filing observations remain unmatched and are excluded from instrument histories.
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
2 filings have incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
8.46×
Peer median 2.92×
EV/EBIT
36.85×
Peer median 32.05×
P/E (TTM)
46.74×
Peer median 32.45×
Price/Sales (TTM)
8.54×
Peer median 2.65×
Price/Book
9.77×
Peer median 2.76×

Peer medians compare against the 21 similar-size Medical Instruments & Supplies companies (of 53 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Proprietary Products $2,492,100,000 $2,334,500,000 $2,397,300,000 $2,406,800,000 $2,317,300,000 $1,648,600,000 $1,398,600,000 $1,308,600,000
Contract Manufactured Products $582,000,000 $558,700,000 $552,500,000 $480,400,000 $514,700,000 $498,600,000 $441,500,000 $409,100,000

By Geography (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
United States $1,329,600,000 $1,230,800,000 $1,238,500,000 $1,286,500,000 $1,198,000,000 $975,600,000 $814,700,000 $766,100,000
Other Europe Countries $451,000,000 $385,500,000 $388,100,000 $359,200,000 $341,300,000 $236,800,000 $251,100,000 $230,500,000
Germany $380,300,000 $372,500,000 $406,100,000 $398,700,000 $474,300,000 $282,100,000 $236,300,000 $235,900,000
Other Countries $353,300,000 $339,000,000 $348,500,000 $364,300,000 $357,400,000 $253,700,000 $213,400,000 $201,800,000
Ireland $333,300,000 $323,200,000 $285,700,000 $240,300,000 $247,600,000 $226,000,000 $173,800,000 $138,100,000
France $226,600,000 $242,200,000 $282,900,000 $237,900,000 $213,000,000 $172,700,000 $150,600,000 $145,000,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Proprietary Products $657,200,000 $577,800,000 $710,100,000 $784,400,000 $796,100,000 $434,500,000 $313,600,000 $266,400,000
Contract Manufactured Products $63,400,000 $72,300,000 $72,100,000 $60,400,000 $67,200,000 $68,600,000 $49,100,000 $44,300,000
Corporate and Eliminations — — — — — — -$66,100,000 -$70,400,000

Operating Margin by Segment (%)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Proprietary Products 26.4% 24.8% 29.6% 32.6% 34.4% 26.4% 22.4% 20.4%
Contract Manufactured Products 10.9% 12.9% 13% 12.6% 13.1% 13.8% 11.1% 10.8%
Key facts CIK 105770 CUSIP 955306105 13F (30d) 681 filings 624 filers Visit website Investor relations